SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 8, 2021
Qualigen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
2042 Corte Del Nogal, Carlsbad, California 92011
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
|Common Stock, par value $.001 per share||QLGN||The Nasdaq Capital Market of The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]
Item 8.01 Other Events.
Qualigen Therapeutics, Inc., a biotechnology company primarily focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that it has withdrawn the Emergency Use Authorization application which it had submitted to the US Food and Drug Administration in June 2020 for its FastPack® SARS-CoV-2 IgG diagnostic test for COVID-19 antibodies. During the nine months during which the emergency application was with the FDA, alternative tests and testing practices have taken hold and we believe there is no longer a viable business case for scale-up of the test.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|QUALIGEN THERAPEUTICS, INC.|
|Date: April 9, 2021||By:||/s/ Michael S. Poirier|
|Michael S. Poirier, President and Chief Executive Officer|